BB Biotech Stock

BB Biotech EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BB Biotech (BION.SW) as of Aug 17, 2026 is 586.83 M CHF. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 84.40 M CHF — a change of 595.29% (higher).

EBITDA

586.83 MCHF

YoY

595.29%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BB Biotech is 2026 586.83 M CHF. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BB Biotech was 2025 84.40 M CHF. It decreases by 595.29% higher compared to the previous year.
Access this data via the Eulerpool API

BB Biotech Stock analysis

What does BB Biotech do? BB Biotech AG is a Swiss investment company specializing in biotechnology and life sciences. The company was founded in 1993 and has been listed on the SIX Swiss Exchange since 1995. BB Biotech AG primarily invests in publicly traded companies in Europe and North America that are active in the biotechnology and healthcare industry. The business model of BB Biotech AG is based on a combination of active portfolio management and long-term investment strategy. The company invests in stocks of biotechnology and healthcare companies that typically do not yet generate profits but are developing promising products or technologies. BB Biotech AG focuses on high portfolio diversification to minimize risk. BB Biotech AG is divided into three business areas: biotechnology, pharmaceuticals, and medtech. The emphasis is on biotechnology, where the company invests in stocks of well-known biotech companies such as Celgene, Gilead Sciences, Regeneron, and Biogen. In the pharmaceutical sector, BB Biotech AG invests in large pharmaceutical companies like Roche, Novartis, or Pfizer. In the medtech sector, the company invests in companies specializing in the development of medical devices and instruments, such as Intuitive Surgical or Neurocrine Biosciences. BB Biotech AG provides added value to its investors through continuous monitoring of the companies in the portfolio and risk management. The company ensures that investors are always informed about the latest developments in the biotechnology and healthcare industry and regularly publishes reports about the portfolio. The portfolio of BB Biotech AG consists of over 30 different biotech, pharmaceutical, and medtech companies. The main holdings of BB Biotech AG are Celgene, Gilead Sciences, Biogen, Incyte, Vertex Pharmaceuticals, Regeneron, and Neurocrine Biosciences. Celgene is one of the world's leading biotech companies specializing in the development of drugs against cancer and other serious diseases. Gilead Sciences is a biotech company specializing in the research of new therapies for the treatment of infectious diseases such as HIV and hepatitis. Biogen is a biotech company specializing in the treatment of neurological disorders such as multiple sclerosis. Incyte is a biotech company specializing in the development of drugs against cancer and inflammatory diseases. Vertex Pharmaceuticals is a biotech company specializing in the treatment of cystic fibrosis. Regeneron is a biotech company specializing in the development of drugs against eye diseases such as macular degeneration and other serious diseases. Neurocrine Biosciences is a medtech company specializing in the development of drugs against sleep disorders and other neurological diseases. BB Biotech AG is an important player in the market for biotechnology and healthcare investments. Through smart selection of investment targets and systematic risk monitoring, the company has enabled investors to achieve high returns with comparatively low risk. Due to these factors, it is now one of the most important holdings in the biotechnology and healthcare sector. BB Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BB Biotech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BB Biotech is 586.83 M CHF in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BB Biotech changed from 84.40 M CHF to 586.83 M CHF, representing a 595.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BB Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CHF is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BB Biotech historically and in real time.

Access this data via the Eulerpool API

Income Statement — BB Biotech

All Key Metrics — BB Biotech